Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2007-08-14
2007-08-14
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S008100, C514S023000, C514S049000, C514S053000, C514S054000, C514S789000
Reexamination Certificate
active
09856391
ABSTRACT:
This invention provides compounds and methods for treating inflammation. The compounds modulate the core2oligosaccharide-mediated binding of inflammatory cells, such as neutrophils, to endothelial cells and other myeloid cells. Significantly, the of the invention methods block inflammation without affecting lymphocyte trafficking. In some embodiments, the compounds inhibit the activity of a core2GlcNAc transferase that is involved in synthesizing the core2oligosaccharides.
REFERENCES:
patent: 2186987 (1998-04-01), None
patent: WO 97/06176 (1997-02-01), None
Jain, R.K. et al. Glycobiology, vool. 8, No. 7, pp. 707-717 (1998).
Hindsgaul, O. et al. J. Biol. Chem. vol. 266, No. 27, pp. 17,858-17,862 (1991).
Nakamura, M. et al. J. Biol. Chem., vol. 273, No. 41, pp. 26,779-789 (1998).
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Chirila, T. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Branch, A., Treands in Biochem Sci. (TIBS), vol. 23, pp. 45-50 (1998).
Elliott, G. et al., Cell, vol. 88, pp. 223-233 (1997).
Pooga, M. et al., FASEB J., vol. 12, pp. 67-77 (1998).
Derossi, d. et al., J. Biol. Chem., vol. 289, No. 14, pp. 10,444-10,450 (1994).
S. Crooke, Antisense Res. and Application, Chapters 1-2, pp. 1-50, Ed. by S. Crooke, Publishers: Springer-Verlag (1998).
DeClercq, E., Biochem. J., vol. 205, pp. 1-13 (1982).
Kyung Book Univ., Report Form No. 911-0403-007-2, pp. 1-3 (1991).
Morin et al., Cancer Res., vol. 43, p. 4 (1983).
Maaheimo et al., “Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion evidence that multivalency enhances the saccharide binding to L-section”,Eur. J. Biochem. 234: 616-625 (1995).
Jain et al., “Inhibition of L- and P-selection by a rationally synthesized novel core 2-like branched structure containing GaINAc-Lewisxand Neu5Acα2-3Galβ1-3GalNAC”,Glycobiology8:7: 707-717 (1998).
Hindsgaul et al., “Evaluation of Deoxygenated Oligosacchararide Acceptor Analogs as Specific Inhibitors of Glycosyltransferases”,The Journal of Biological Chemistry266:27: 17858-17862 (1991).
Ellies et al., “Core 2 Oligosaccharide Biosynthesis Distinguishes between Selection Ligands Essential for Leukocyte Homing and Inflammation”,Immunity9: 881-890 (1998).
Baum, Linda G. et al.; “Human Thymic Epithelial Cells Express an Endogenous Lectin, Galectin-1, which Binds to Core 2 O-Glycans on Thymocytes and T Lymphoblastoid Cells”; 1995,J. Exp. Med., vol. 181, pp. 877-887.
Bierhuizen, Marti F.A. et al.; “Expression cloning of a cDNA encoding UDP-GlcNAc:Galβ1-3-GalNac-R (GlcNAc to GalNAc) β1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma Large tumor antigen”; 1992,Proc. Natl. Acad. Sci:, vol. 89, pp. 9326-9330.
Brockhausen, I. et al.; “Biosynthesis of O-Glycans in Leukocytes from Normal Donors and from Patients with Leukemia: Increase in O-Glycan Core 2 UDP-GlcNAc:Galβ3GalNAcα-R (GlcNAc to GalNAc) β(1-6)-N-Acetylglucosaminyltransferase in Leukemia Cells” 1991,Cancer Research, vol. 51, pp. 1257-1263.
Fox, Robert I. et al.; “A Novel Cell Surface Antigen (T305) Found in Increased Frequency on Acute Leukemia Cells and in Autoimmune Disease States”; 1983,The Journal of Immunology, vol. 131, No. 2, pp. 762-767.
Higgins, Elizabeth A. et al.; “Aberrant O-Linked Oligosaccharide Biosynthesis in Lymphocytes and Platelets from Patients with the Wiskott-Aldrich Syndrome”; 1991,The Journal of Biological Chemistry, vol. 266, No. 10, pp. 6280-6290.
Kumar, Ravindra et al.; “Core2 β-1,6-N-Acetylglucosaminyltransferase Enzyme Activity Is Critical for P-Selectin Glycoprotein Ligand-1 Binding to P-Selectin”; 1988,Blood, vol. 88, No. 10, pp. 3872-3879.
Lasky, Laurence A.; “Selectin-Carbohydrate Interactions and the Initiation of the Inflammatory Response”; 1995,Annu. Rev. Biochem, vol. 64, pp. 113-139.
Lowe, John B.; “Selectin ligands, leukocyte trafficking, and fucosyltransferase genes”; 1997,Kidney International, vol. 51, pp. 1418-1426.
Lowe, John B. et al.: “Perspective Series: Cell Adhesion in Vascular Biology”; 1997,J. Clin. Invest., vol. 99, No. 5, pp. 822-826.
Maly, Petr et al.; “The α (1,3) Fucosyltransferase Fuc-TVII Controls Leukocyte Trafficking through an Essential Role in L-, E-, and P-selection Ligand Biosynthesis”; 1996,Cell, vol. 86, pp. 643-653.
Piller, Friedrich et al.; “Altered O-Glycan Synthesis in Lymphocytes from Patients with Wiskott-Aldrich Syndrome”; 1991,J. Exp. Med., vol. 173, pp. 1501-1510.
Piller, Friedrich et al.; “Human T-lymphocyte Activation Is Associated with Changes in O-Glycan Biosynthesis” 1991,The Journal of Biological Chemistry, vol. 263, No. 29, pp. 15146-15150.
Saitoh, Osamu et al.; “T-Lymphocytic Leukemia Expresses Complex, Branched O-Linked Oligosaccharides on a Mojor Sialoglycoprotein, Leukosialin”; 1991,Blood, vol. 77, No. 7, pp. 1491-1499.
Springer, Timothy A.; “Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration”; 1995,Annu. Rev. Physiol., vol. 57, pp. 827-872.
Tsubol, Shigeru et al.; “Branched O-linked oligosaccharides ectopically expressed in transgenic mice reduce primary T-cell immune responses”; 1997,The EMBO Journal, vol. 16, No. 21, pp. 6364-6373.
Williams, David et al.; “Mucin Synthesis: I. Detection in Canine Submaxillary Glands of an N-Acetylglucosaminyltransferase which acts on Mucin Substrates”; 1980,The Journal of Biological Chemistry, vol. 255, No. 23, pp. 11247-11252.
Ellies Lesliey G.
Marth Jamey D.
Townsend & Townsend & Crew
Zara Jane
LandOfFree
Use of core 2 G1cNAc transferase inhibitors in treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of core 2 G1cNAc transferase inhibitors in treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of core 2 G1cNAc transferase inhibitors in treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3899149